表紙
市場調查報告書

疫苗製造前20名公司的簡介 (2019年)

Top 20 Vaccines Manufacturers 2019: Merck & Co., Sanofi, Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Emergent Biosolutions, Other Companies

出版商 Visiongain Ltd 商品編碼 822044
出版日期 內容資訊 英文 157 Pages
商品交期: 最快1-2個工作天內
價格
疫苗製造前20名公司的簡介 (2019年) Top 20 Vaccines Manufacturers 2019: Merck & Co., Sanofi, Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Emergent Biosolutions, Other Companies
出版日期: 2019年02月12日內容資訊: 英文 157 Pages
簡介

本報告提供全球疫苗製造的市場調查,市場定義和概要,各地區的需求成果,市場規模的變化與預測,市場成長的促進因素、阻礙要素分析,前20名公司的排行榜,前20名公司的詳細簡介 (企業概要、財務的展望、產品系列、策略性部署等) 彙整。

第1章 報告概要

第2章 簡介:全球人體疫苗市場

  • 市場定義
  • 市場區隔
    • 類型
      • 不活化疫苗
      • 減毒活病毒疫苗
      • 結合型疫苗
      • 重組載體疫苗
    • 用途
      • 兒童用
      • 成人用
      • 老年人用
      • 旅遊用
      • 治療用
  • 地區需求
    • 美國
    • 歐洲
    • 日本

第3章 全球疫苗市場展望

  • 全球市場現況
  • 產業趨勢:變化、預測
  • 成長推動因素、課題、市場機會

第4章 主要20家公司的排行榜

  • 主要20家公司的排行榜
  • 全球市場的變化、預測

第5章 疫苗製造前20名公司

  • Merck & Co., Inc.
  • Sanofi
  • Pfizer
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • AstraZeneca
  • Emergent Biosolutions
  • CSL Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Astellas Pharma Inc.
  • SELLAS Life Sciences Group, Inc.
  • Novavax, Inc.
  • Inovio Pharmaceuticals
  • 田邊三菱製藥
  • Sun Pharmaceutical Industries Ltd.
  • Gilead Sciences
  • F. Hoffmann-La Roche Ltd.
  • 武田藥品工業
  • Teva Pharmaceutical
  • Bavarian Nordic
    • 財務的展望
    • 產品系列
    • 策略性部署等

第6章 SWOT分析

第7章 總論

目錄
Product Code: PHA0355

The global vaccines market has witnessed strong growth in past few years. The top 5 manufacturers in the global vaccines market are, Merck & Co., Inc., Sanofi, Pfizer Inc., GlaxoSmithKline PLC, and Johnson & Johnson. These companies secured about 76% revenue share in the global vaccines market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you will find 157-page report and you will receive 90 tables and 75 figures - all unavailable elsewhere.

The 157-page report provides clear detailed insight into the Top 20 Vaccines Manufacturers 2019. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Assessment of the leading companies in the global vaccines market:

  • Astellas Pharma Inc.
  • AstraZeneca
  • Bavarian Nordic
  • CSL Ltd.
  • Emergent Biosolutions, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi
  • SELLAS Life Sciences Group, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical

This report discusses financial outlook, product portfolio and strategic developments.

  • Revenues forecast from 2017-2028 for the US, Europe and Japan Vaccines Market.
  • Market share of key companies in the vaccines market.
  • Market share of leading vaccines in the global vaccines market.
  • Drivers, Challenges and Opportunities for the global vaccines market.
  • A SWOT analysis of the global vaccines market.

Visiongain's study is intended for anyone requiring commercial analyses for the Top 20 Vaccines Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 20 Vaccines Manufacturers 2019: Merck & Co., Sanofi, Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Emergent Biosolutions, Other Companies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the Global Vaccines Market
  • 1.2. Why You Should Read This Report
  • 1.3. Benefits of This Report
  • 1.4. Report Structure
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.6.1. Primary Research
  • 1.6.2. Secondary Research
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to the World Human Vaccines Market

  • 2.1. Vaccines Market Definition
  • 2.2. Vaccines Market Segmentation
    • 2.2.1. Vaccine Types:
      • 2.2.1.1. Inactivated Vaccines
      • 2.2.1.2. Live Attenuated Vaccines
      • 2.2.1.3. Conjugate Vaccines
      • 2.2.1.4. Recombinant Vector Vaccines
    • 2.2.2. Vaccine Submarket
      • 2.2.2.1. Paediatric vaccines
      • 2.2.2.2. Adult vaccines
      • 2.2.2.3. Elderly vaccines
      • 2.2.2.4. Travel vaccines
      • 2.2.2.5. Therapeutic Vaccines
  • 2.3. Demand for Vaccines in Regional Markets
    • 2.3.1. U.S. Vaccines Market Overview - 2018
    • 2.3.2. Europe Vaccines Market Overview- 2018
    • 2.3.3. Japan Vaccines Market Overview- 2018

3. World Vaccine Market Outlook, 2017-2028

  • 3.1. Global Vaccines Market 2018 Overview
  • 3.2. The World Vaccine Market: Industry Trends, 2017-2028
  • 3.3. Drivers and Challenges for the Global Vaccines Market
    • 3.3.1. Drivers
      • 3.3.1.1. Growing demand from emerging markets
      • 3.3.1.2. Increasing birth rates in developing countries
      • 3.3.1.3. Rise in ageing population globally
    • 3.3.2. Challenges
      • 3.3.2.1. Funding can be difficult to sustain
      • 3.3.2.2. Oligarchic market presents barrier to entry
    • 3.3.3. Opportunities
      • 3.3.3.1. Advancements in vaccine technology and a strong culture of innovation and R&D pipelines
      • 3.3.3.2. Growing awareness of benefits of vaccinations amongst adults

4. Leading 20 Companies Ranking in the Vaccines Market

  • 4.1. Leading 20 Companies Ranking in the Vaccines Market 2018
  • 4.2. Global Vaccines Market Forecast, 2017-2028

5. Top 20 Vaccines Manufacturers

  • 5.1. Merck & Co., Inc. Overview
    • 5.1.1. Merck Financial Outlook
    • 5.1.2. Merck Product Portfolio
    • 5.1.3. Merck Strategic Developments
  • 5.2. Sanofi Overview
    • 5.2.1. Sanofi Financial Outlook
    • 5.2.2. Sanofi Product Portfolio
    • 5.2.3. Sanofi Strategic Developments
  • 5.3. Pfizer Overview
    • 5.3.1. Pfizer Financial Outlook
    • 5.3.2. Pfizer Product Portfolio
    • 5.3.3. Pfizer Strategic Developments
  • 5.4. GlaxoSmithKline PLC Overview
    • 5.4.1. GlaxoSmithKline PLC Financial Outlook
    • 5.4.2. GlaxoSmithKline PLC Product Portfolio
    • 5.4.3. GlaxoSmithKline PLC Strategic Developments
  • 5.5. Johnson & Johnson Overview
    • 5.5.1. Johnson & Johnson Financial Outlook
    • 5.5.2. Johnson & Johnson Product Portfolio
    • 5.5.3. Johnson & Johnson Strategic Developments
  • 5.6. AstraZeneca Overview
    • 5.6.1. AstraZeneca Financial Outlook
    • 5.6.2. AstraZeneca Product Portfolio
    • 5.6.3. AstraZeneca Strategic Developments
  • 5.7. Emergent Biosolutions Overview
    • 5.7.1. Emergent Biosolutions Financial Outlook
    • 5.7.2. Emergent Biosolutions Product Portfolio
    • 5.7.3. Emergent Biosolutions Strategic Developments
  • 5.8. CSL Ltd. Overview
    • 5.8.1. CSL Ltd. Financial Outlook
    • 5.8.2. CSL Ltd. Product Portfolio
    • 5.8.3. CSL Ltd. Strategic Developments
  • 5.9. Serum Institute of India Pvt. Ltd. Overview
    • 5.9.1. Serum Institute of India Pvt. Ltd. Financial Outlook
    • 5.9.2. Serum Institute of India Pvt. Ltd. Product Portfolio
    • 5.9.3. Serum Institute of India Pvt. Ltd. Strategic Developments
  • 5.10. Astellas Pharma Overview
    • 5.10.1. Astellas Pharma Financial Outlook
    • 5.10.2. Astellas Pharma Product Portfolio
  • 5.10.3. Astellas Pharma Strategic Developments
  • 5.11. SELLAS Life Sciences Group, Inc. Overview
    • 5.11.1. SELLAS Life Sciences Group, Inc. Financial Outlook
    • 5.11.2. SELLAS Life Sciences Group, Inc. Product Portfolio
    • 5.11.3. SELLAS Life Sciences Group, Inc. Strategic Developments
  • 5.12. Novavax, Inc. Overview
    • 5.12.1. Novavax, Inc. Financial Outlook
    • 5.12.2. Novavax, Inc. Product Portfolio
  • 5.13. Inovio Pharmaceuticals Overview
    • 5.13.1. Inovio Pharmaceuticals Financial Outlook
    • 5.13.2. Inovio Pharmaceuticals Product Portfolio
    • 5.13.3. Inovio Pharmaceuticals Strategic Developments
  • 5.14. Mitsubishi Tanabe Pharma Corporation Overview
    • 5.14.1. Mitsubishi Tanabe Pharma Corporation Financial Outlook
    • 5.14.2. Mitsubishi Tanabe Pharma Corporation Product Portfolio
    • 5.14.3. Mitsubishi Tanabe Pharma Corporation Strategic Developments
  • 5.15. Sun Pharmaceutical Industries Ltd. Overview
    • 5.15.1. Sun Pharmaceutical Industries Ltd. Financial Outlook
    • 5.15.2. Sun Pharmaceutical Industries Ltd. Product Portfolio
    • 5.15.3. Sun Pharmaceutical Industries Ltd. Strategic Developments
  • 5.16. Gilead Sciences Overview
    • 5.16.1. Gilead Sciences Financial Outlook
    • 5.16.2. Gilead Sciences Product Portfolio
    • 5.16.3. Gilead Sciences Strategic Developments
  • 5.17. F. Hoffmann-La Roche Ltd. Overview
    • 5.17.1. F. Hoffmann-La Roche Ltd. Financial Outlook
    • 5.17.2. F. Hoffmann-La Roche Ltd. Product Portfolio
    • 5.17.3. F. Hoffmann-La Roche Ltd. Strategic Developments
  • 5.18. Takeda Pharmaceutical Company Limited Overview
    • 5.18.1. Takeda Pharmaceutical Company Limited. Financial Outlook
    • 5.18.2. Takeda Pharmaceutical Company Limited. Product Portfolio
    • 5.18.3. Takeda Pharmaceutical Company Limited. Strategic Developments
  • 5.19. Teva Pharmaceutical Overview
    • 5.19.1. Teva Pharmaceutical Financial Outlook
    • 5.19.2. Teva Pharmaceutical Product Portfolio
    • 5.19.3. Teva Pharmaceutical Strategic Developments
  • 5.20. Bavarian Nordic Overview
    • 5.20.1. Bavarian Nordic Financial Outlook
    • 5.20.2. Bavarian Nordic Product Portfolio
    • 5.20.3. Bavarian Nordic Strategic Developments

6. SWOT Analysis of the Global Vaccines Market, 2018

  • 6.1. Strengths
  • 6.2. Weaknesses
  • 6.3. Opportunities
  • 6.4. Threats

7. Conclusion

  • 7.1. Strong and Diverse Research and Development
  • 7.2. Oligarchic market presents
  • 7.3. Emerging Markets: High Demand for Vaccines
  • 7.4. Top 20 Companies and Revenue
  • Appendices
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1: The US Vaccines Revenue Forecast ($bn) and Annual Growth (%), 2017-2028
  • Table 2.2: The Europe Vaccines Revenue Forecast ($bn) and Annual Growth (%), 2017-2028
  • Table 2.3: Japan Vaccines Revenue Forecast ($bn) and Annual Growth (%), 2017-2028
  • Table 4.1: Companies Profiled in this Report and Country HQ
  • Table 4.2: Global Vaccines Revenue Forecast ($bn) and Annual Growth (%), 2017-2028
  • Table 5.1: Merck & Co., Inc.: Key Facts, 2017
  • Table 5.2: Merck & Co., Inc.: Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.3: Merck & Co., Inc.: Product Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.4: Merck & Co., Inc.: Vaccines Clinical Pipeline
  • Table 5.5: Merck & Co., Inc.: Vaccines Revenue ($million), AGR (%) 2015-2017
  • Table 5.6: Merck & Co., Inc.: Vaccines Product Revenue ($million) and Revenue Shares (%), 2017
  • Table 5.7: Merck & Co., Inc.: Strategic Developments, 2015-2018
  • Table 5.8: Sanofi: Key Facts, 2017
  • Table 5.9: Sanofi: Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.10: Sanofi: Vaccines Clinical Pipeline
  • Table 5.11: Sanofi: Vaccines Revenue ($million), AGR (%) 2015-2017
  • Table 5.12: Sanofi: Vaccines Product Revenue ($million) and Revenue Shares (%), 2017
  • Table 5.13: Sanofi: Strategic Developments, 2015-2018
  • Table 5.14: Pfizer: Key Facts, 2017
  • Table 5.15: Pfizer: Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.16: Pfizer: Product Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.17: Pfizer: Vaccines Clinical Pipeline
  • Table 5.18: Pfizer: Vaccines Revenue ($million), AGR (%) 2015-2017
  • Table 5.19: Pfizer: Vaccines Product Revenue ($million) and Revenue Shares (%), 2017
  • Table 5.20: Pfizer: Strategic Developments, 2015-2018
  • Table 5.21: GlaxoSmithKline PLC: Key Facts, 2017
  • Table 5.22: GlaxoSmithKline PLC: Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.23: GlaxoSmithKline PLC: Product Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.24: GlaxoSmithKline PLC: Vaccines Clinical Pipeline
  • Table 5.25: GlaxoSmithKline PLC: Vaccines Revenue ($million), AGR (%) 2015-2017
  • Table 5.26: GlaxoSmithKline PLC: Vaccines Product Revenue ($million) and Revenue Shares (%), 2017
  • Table 5.27: GlaxoSmithKline PLC: Strategic Developments, 2015-2018
  • Table 5.28: Johnson & Johnson: Key Facts, 2018
  • Table 5.29: Johnson & Johnson: Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.30: Johnson & Johnson: Product Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.31: Johnson & Johnson: Vaccines Clinical Pipeline
  • Table 5.32: Johnson & Johnson: Infectious Diseases and Vaccines Revenue ($million), AGR (%) 2015-2017
  • Table 5.33: Johnson & Johnson: Vaccines Product Revenue ($million) and Revenue Shares (%), 2017
  • Table 5.34: Johnson & Johnson: Strategic Developments, 2015-2018
  • Table 5.35: AstraZeneca: Key Facts, 2018
  • Table 5.36: AstraZeneca: Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.37: AstraZeneca: Infectious Diseases and Vaccines Revenue ($million), AGR (%) 2015-2017
  • Table 5.38: AstraZeneca: Vaccines Product Revenue ($million) and Revenue Shares (%), 2017
  • Table 5.39: AstraZeneca: Strategic Developments, 2015-2018
  • Table 5.40: Emergent Biosolutions: Key Facts, 2018
  • Table 5.41: Emergent Biosolutions: Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 5.42: Emergent Biosolutions: Vaccines Clinical Pipeline
  • Table 5.43: Emergent Biosolutions: Strategic Developments, 2015-2018
  • Table 5.44: CSL Ltd.: Key Facts, 2018
  • Table 5.45: CSL Ltd.: Revenue ($million) and Revenue Shares (%) by Reporting Segment, 2018
  • Table 5.46: CSL Ltd.: Vaccines Clinical Pipeline
  • Table 5.47: CSL Ltd.: Strategic Developments, 2015-2018
  • Table 5.48: Serum Institute of India Pvt. Ltd.: Key Facts, 2018
  • Table 5.49: Serum Institute of India Pvt. Ltd.: Strategic Developments, 2015-2018
  • Table 5.50: Astellas Pharma: Key Facts, 2018
  • Table 5.51: Astellas Pharma: Revenue ($million) and Revenue Shares (%) by Product, 2018
  • Table 5.52: Astellas Pharma: Vaccines Clinical Pipeline
  • Table 5.53: Astellas Pharma: Strategic Developments, 2015-2018
  • Table 5.54: SELLAS Life Sciences Group, Inc.: Key Facts, 2018
  • Table 5.55: SELLAS Life Sciences Group, Inc.: Vaccines Clinical Pipeline
  • Table 5.56: SELLAS Life Sciences Group, Inc.: Strategic Developments, 2015-2018
  • Table 5.57: Novavax, Inc.: Key Facts, 2018
  • Table 5.58: Novavax, Inc.: Vaccines Clinical Pipeline
  • Table 5.59: Inovio Pharmaceuticals: Key Facts, 2018
  • Table 5.60: Inovio Pharmaceuticals: Vaccines Clinical Pipeline
  • Table 5.61: Inovio Pharmaceuticals: Strategic Developments, 2015-2018
  • Table 5.62: Mitsubishi Tanabe Pharma Corporation: Key Facts, 2018
  • Table 5.63: Mitsubishi Tanabe Pharma Corporation: Revenue ($million) and Revenue Shares (%) by Product Type, 2017
  • Table 5.64: Mitsubishi Tanabe Pharma Corporation: Vaccines Clinical Pipeline
  • Table 5.65: Mitsubishi Tanabe Pharma Corporation: Vaccines Revenue ($million), AGR (%) 2015-2017
  • Table 5.66: Mitsubishi Tanabe Pharma Corporation: Vaccines Product Revenue ($million) and Revenue Shares (%), 2017
  • Table 5.67: Mitsubishi Tanabe Pharma Corporation: Strategic Developments, 2015-2018
  • Table 5.68: Sun Pharmaceutical Industries Ltd.: Key Facts, 2018
  • Table 5.69: Sun Pharmaceutical Industries Ltd.: Strategic Developments, 2015-2018
  • Table 5.70: Gilead Sciences: Key Facts, 2018
  • Table 5.71: Gilead Sciences: Revenue ($million) and Revenue Shares (%) by Segment, 2017
  • Table 5.72: Gilead Sciences: Strategic Developments, 2015-2018
  • Table 5.73: F. Hoffmann-La Roche Ltd.: Key Facts, 2018
  • Table 5.74: F. Hoffmann-La Roche Ltd.: Vaccines Clinical Pipeline
  • Table 5.75: F. Hoffmann-La Roche Ltd.: Strategic Developments, 2015-2018
  • Table 5.76: Takeda Pharmaceutical Company Limited: Key Facts, 2018
  • Table 5.77: Takeda Pharmaceutical Company: Vaccines Clinical Pipeline
  • Table 5.78: Takeda Pharmaceutical Company: Strategic Developments, 2015-2018
  • Table 5.79: Teva Pharmaceutical: Key Facts, 2018
  • Table 5.80: Teva Pharmaceutical: Revenue ($million) and Revenue Shares (%) by Segment, 2017
  • Table 5.81: Teva Pharmaceutical: Strategic Developments, 2015-2018
  • Table 5.82: Bavarian Nordic: Key Facts, 2018
  • Table 5.83: Bavarian Nordic: Vaccines Clinical Pipeline
  • Table 5.84: Bavarian Nordic: Strategic Developments, 2015-2018
  • Table 7.1: Top 20 Companies and Revenue, 2017 ($million)

List of Figures

  • Figure 4.1: Market Share of Key Companies in the Vaccines Market (%), 2017
  • Figure 4.2: Market Share of Leading Vaccines in the Market (%), 2017
  • Figure 4.3: Global Vaccines Revenue ($bn), 2017-2028
  • Figure 5.1: Merck & Co., Inc.: Historical Revenues ($million), 2013-2017
  • Figure 5.2: Merck & Co., Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 5.3: Merck & Co., Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 5.4: Merck & Co., Inc.: Revenue Shares (%) by Region, 2017
  • Figure 5.5: Merck & Co., Inc.: Diagnostics Revenue ($million), 2015-2017
  • Figure 5.6: Merck & Co., Inc.: Vaccines Product Revenue Shares (%), 2017
  • Figure 5.7: Sanofi: Historical Revenues ($million), 2013-2017
  • Figure 5.8: Sanofi: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 5.9: Sanofi: Revenue Shares (%) by Region, 2017
  • Figure 5.10: Sanofi: Diagnostics Revenue ($million), 2015-2017
  • Figure 5.11: Sanofi: Vaccines Product Revenue Shares (%), 2017
  • Figure 5.12: Pfizer: Historical Revenues ($million), 2013-2017
  • Figure 5.13: Pfizer: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 5.14: Merck & Co., Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 5.15: Pfizer: Revenue Shares (%) by Region, 2017
  • Figure 5.16: Pfizer: Diagnostics Revenue ($million), 2015-2017
  • Figure 5.17: Pfizer: Vaccines Product Revenue Shares (%), 2017
  • Figure 5.18: GlaxoSmithKline PLC: Historical Revenues ($million), 2013-2017
  • Figure 5.19: GlaxoSmithKline PLC: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 5.20: GlaxoSmithKline PLC: Revenue Shares (%) by Product, 2017
  • Figure 5.21: GlaxoSmithKline PLC: Revenue Shares (%) by Region, 2017
  • Figure 5.22: GlaxoSmithKline PLC: Diagnostics Revenue Shares (%), 2017
  • Figure 5.23: GlaxoSmithKline PLC: Vaccines Revenue Shares (%), 2017
  • Figure 5.24: GlaxoSmithKline PLC: Vaccines Revenue by Region ($million), 2017
  • Figure 5.25: Johnson & Johnson: Historical Revenues ($million), 2013-2017
  • Figure 5.26: Johnson & Johnson: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 5.27: Johnson & Johnson: Revenue Shares (%) by Product, 2017
  • Figure 5.28: Johnson & Johnson: Revenue Shares (%) by Region, 2017
  • Figure 5.29: Johnson & Johnson: Diagnostics Revenue ($million), 2015-2017
  • Figure 5.30: Johnson & Johnson: Vaccines Revenue Shares (%), 2017
  • Figure 5.31: AstraZeneca: Historical Revenues ($million), 2013-2017
  • Figure 5.32: AstraZeneca: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 5.33: AstraZeneca: Revenue Shares (%) by Region, 2017
  • Figure 5.34: AstraZeneca: Diagnostics Revenue ($million), 2015-2017
  • Figure 5.35: AstraZeneca: Vaccines Revenue Shares (%), 2017
  • Figure 5.36: AstraZeneca: Vaccines Revenue by Region ($million), 2017
  • Figure 5.37: Emergent Biosolutions: Historical Revenues ($million), 2013-2017
  • Figure 5.38: Emergent Biosolutions: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 5.39: Emergent Biosolutions: Revenue Shares (%) by Region, 2017
  • Figure 5.40: CSL Ltd.: Historical Revenues ($million), 2013-2017
  • Figure 5.41: CSL Ltd.: Revenue Shares (%) by Reporting Segment, 2018
  • Figure 5.42: CSL Ltd.: Revenue Shares (%) by Region, 2017
  • Figure 5.43: Astellas Pharma: Historical Revenues ($million), 2014-2018
  • Figure 5.44: Astellas Pharma: Revenue Shares (%) by Product, 2018
  • Figure 5.45: Astellas Pharma: Revenue Shares (%) by Region, 2018
  • Figure 5.46: Novavax, Inc.: Historical Revenues ($million), 2013-2017
  • Figure 5.47: Inovio Pharmaceuticals: Historical Revenues ($million), 2013-2017
  • Figure 5.48: Mitsubishi Tanabe Pharma Corporation: Historical Revenues ($million), 2013-2017
  • Figure 5.49: Mitsubishi Tanabe Pharma Corporation: Revenue Shares (%) by Product Type, 2017
  • Figure 5.50: Mitsubishi Tanabe Pharma Corporation: Revenue Shares (%) by Ethical Products, 2017
  • Figure 5.51: Mitsubishi Tanabe Pharma Corporation: Revenue Shares (%) by Region, 2017
  • Figure 5.52: Mitsubishi Tanabe Pharma Corporation: Diagnostics Revenue ($million), 2015-2017
  • Figure 5.53: Mitsubishi Tanabe Pharma Corporation: Vaccines Revenue Shares (%), 2017
  • Figure 5.54: Sun Pharmaceutical Industries Ltd.: Historical Revenues ($million), 2014-2018
  • Figure 5.55: Sun Pharmaceutical Industries Ltd.: Revenue Shares (%) by Region, 2018
  • Figure 5.56: Gilead Sciences: Historical Revenues ($million), 2013-2017
  • Figure 5.57: Gilead Sciences: Revenue Shares (%) by Segment, 2017
  • Figure 5.58: Gilead Sciences: Revenue Shares (%) by Product Type, 2017
  • Figure 5.59: Gilead Sciences: Revenue Shares (%) by Products, 2017
  • Figure 5.60: Gilead Sciences: Revenue Shares (%) by Region, 2017
  • Figure 5.61: F. Hoffmann-La Roche Ltd.: Historical Revenues ($million), 2013-2017
  • Figure 5.62: Mitsubishi Tanabe Pharma Corporation: Revenue Shares (%) by Product Type, 2018
  • Figure 5.63: F. Hoffmann-La Roche Ltd.: Revenue Shares (%) by Region, 2018
  • Figure 5.64: Takeda Pharmaceutical Company Limited: Historical Revenues ($million), 2014-2018
  • Figure 5.65: Takeda Pharmaceutical Company Limited: Revenue Shares (%) by Product Type, 2018
  • Figure 5.66: Takeda Pharmaceutical Company Limited: Revenue Shares (%) by Region, 2018
  • Figure 5.67: Teva Pharmaceutical: Historical Revenues ($million), 2013-2017
  • Figure 5.68: Teva Pharmaceutical: Revenue Shares (%) by Product Type, 2017
  • Figure 5.69: Teva Pharmaceutical: Revenue Shares (%) by Region, 2017
  • Figure 5.70: Bavarian Nordic: Historical Revenues ($million), 2013-2017
  • Figure 5.71: Bavarian Nordic: Revenue Shares (%) by Region, 2017
  • Figure 6.1: SWOT Analysis of the Global Vaccines Market, 2018

COMPANIES LISTED:

  • AELIX Therapeutics
  • Afferent Pharmaceuticals
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bavarian Nordic A/S
  • Bayer
  • BIKEN Co. Ltd.
  • BioJect Medical Technologies Inc.
  • Biological E. Limited
  • BioNTech
  • CSL Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dyadic International, Inc.
  • Emergent Biosolutions, Inc.
  • Evaxion Biotech
  • F. Hoffmann-La Roche Ltd.
  • Ganymed Pharmaceuticals AG
  • Genentech, Inc.
  • GeneOne Life Science Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • GlaxoWellcome
  • GlobeImmune
  • GlycoVaxyn AG
  • Hitachi Ltd.
  • HitGen Ltd.
  • Hookipa Pharma
  • Immunomic Therapeutics, Inc.
  • Inovio Pharmaceuticals Inc.
  • IOmet
  • Janssen Pharmaceutical Companies
  • Janssen Vaccines & Prevention B.V.
  • Johnson & Johnson
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna
  • Nanotherapeutics
  • Novavax, Inc.
  • PaxVax
  • Pfizer Inc.
  • Plumbline Life Sciences, Inc.
  • Poonawalla Investment & Industries Pvt. Ltd.
  • Potenza Therapeutics, Inc.
  • Protein Sciences
  • Regeneron Pharmaceuticals, Inc.
  • Roche
  • Sanofi
  • SELLAS Life Sciences Group, Inc.
  • Seqirus
  • Serum Institute of India Pvt. Ltd.
  • Shionogi
  • SmithKline Beecham
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical
  • Valneva SE
  • Zydus Cadila

List of Organizations Mentioned in the Report:

  • Biomedical Advanced Research and Development Authority (BARDA)
  • Centers for Disease Control and Protection (CDC)
  • Defense Advanced Research Projects Agency
  • Drexel University
  • Global Alliance for Vaccines and Immunization (GAVI)
  • International Centre for Genetic Engineering and Biotechnology (ICGEB)
  • Mayo Clinic
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • National Microbiology Laboratory of the Public Health Agency of Canada
  • Oswaldo Cruz Foundation
  • Pan American Health Organization (PAHO)
  • The Jenner Institute
  • The Ministry of Health, Labour and Welfare and the Health Service Bureau
  • The National Institute of Virology (NIV), Pune
  • The Parker Institute for Cancer Immunotherapy
  • The US Department of Health and Human Services (HHS)
  • The Wistar Institute
  • U.S. Army Medical Research Institute of Infectious Diseases
  • UNICEF
  • University of Oxford
  • University of Pennsylvania
  • University of Tokyo
  • Walter Reed Army Institute of Research